This review synthesizes 2-year results from the BE HEARD phase 3 trials and their extension, demonstrating that dual IL-17A/F inhibition with bimekizumab provides deep, durable clinical responses and a favorable safety profile for patients with moderate-to-severe hidradenitis suppurativa.